Atlas Trials

Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents

Clinical trial NCT03185039 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03185039
Sponsor
Institut Paoli-Calmettes
Status
ACTIVE_NOT_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Kidney Cancer
Start date
2017-05-29
Primary completion
2026-12-19
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.